Patents Examined by Malgorzata A. Walicka
  • Patent number: 7524665
    Abstract: The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: April 28, 2009
    Assignee: University of North Carolina at Chapel Hill
    Inventors: Darrel W. Stafford, Tao Li
  • Patent number: 7482136
    Abstract: Human BACE polypeptides having modifications to the N-linked glycosylation sites including one or more of the following amino acid substitutions: S174I, N223A, N153Q and N354S. DNA sequences, vectors, and host cells for producing the polypeptides. Crystalline protein compositions formed from the purified polypeptides. Methods of screening for compounds that inhibit A? using the polypeptides.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: January 27, 2009
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John Anderson, Lisa McConlogue, Guriqbal Basi, Sukanto Sinha
  • Patent number: 7482141
    Abstract: The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: January 27, 2009
    Assignee: University of North Carolina at Chapel Hill
    Inventors: Darrel W. Stafford, Tao Li
  • Patent number: 7456007
    Abstract: Disclosed is an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (APP and APPsw) are also disclosed. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: December 24, 1999
    Date of Patent: November 25, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Patent number: 7452710
    Abstract: The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (dhaT).
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: November 18, 2008
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Mark Emptage, Sharon L. Haynie, Lisa A. Laffend, Jeff P. Pucci, Gregory Whited
  • Patent number: 7435571
    Abstract: The present Invention relates to enzymes involved in the Synthesis of Coenzyme Q-10, i.e., decaprenyl diphosphate (DPP) synthase and 4-hydroxybenzoate polyprenyltransferase, to isolated DNA encoding said enzymes and to methods for the microbial production of Coenzyme Q-10.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: October 14, 2008
    Assignee: DSM IP Assets B.V.
    Inventors: Markus Huembelin, Rual Lopez-Ulibarri, John B. Perkins, Ghislain Schyns
  • Patent number: 7427478
    Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: September 23, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Patent number: 7422887
    Abstract: To provide a novel phospholipase A2 (PLA2) associated with psoriasis, a nucleic acid encoding the same, a method for characterizing, identifying or screening an inhibitor for the PLA2 or a medicament; and a novel method for diagnosis or examination of psoriasis or the like. A polypeptide having the amino acid sequence shown in SEQ ID NO: 9, a conservative substitution variant thereof, a naturally occurring allelic variant thereof, or the like. A nucleic acid encoding the above-mentioned polypeptide, a complement thereof or the like. A method for characterizing, identifying or screening an inhibitor for the PLA2 or a medicament, using the above-mentioned polypeptide. An examination method for psoriasis, characterized by assaying an expression level of a gene consisting of the above-mentioned nucleic acid or the like.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: September 9, 2008
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Yuji Imai, Koji Wakimoto, Hiroaki Chiba
  • Patent number: 7422873
    Abstract: CrtW carotenoid ketolases are provided useful for the production of astaxanthin. The ketolases genes of the present invention exhibit improved ketolase activity when converting cyclic hydroxylated carotenoid intermediates into astaxanthin. Recombinant expression of the present carotenoid ketolases in host cell producing cyclic hydroxylated carotenoid intermediates enabled increased production of astaxanthin.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 9, 2008
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Kristen Janet Stead, Henry Yao, Rick W. Ye
  • Patent number: 7422886
    Abstract: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signaling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodeling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110? which interacts with p85, has a broad phosphinositide specificity and is sensitive to the same kinase inhibitors as PI3 Kinase p110A. However, in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110? is selectively expressed in leucocytes. Importantly, p110? shows enhanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: September 9, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bart Vanhasebroeck, Michael Derek Waterfield
  • Patent number: 7419812
    Abstract: Th invention is directed to nucleic acid sequences which encode polypeptides having PhzO activity, namely, the ability to convert phenazine-1-carboxylic acid to a 2-hydroxylated phenazine, and isolated polypeptides having this activity. The invention is also directed to recombinant nucleic acid molecules, vectors, and host cells including the nucleic acid sequences as well as methods for producing and using the polypeptides, including expression in bacterial or plant cells to inhibit fungal pathogens.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: September 2, 2008
    Assignees: The United States of America as represented by the Secretary of Agriculture, Washington State University Research Foundation
    Inventors: Linda S. Thomashow, Shannon M. Delaney, Dmitri V. Mavrodi, David M. Weller
  • Patent number: 7416871
    Abstract: A highly thermo-stable lactate oxidase has been provided by, in the lactate oxidase obtained from Aerococcus viridans, modifying the 6 amino acid residues.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: August 26, 2008
    Assignee: NEC Corporation
    Inventor: Hirotaka Minagawa
  • Patent number: 7410638
    Abstract: The present invention relates to isolated nucleic acid molecules encoding an autoinducer inactivation protein, wherein the encoded protein comprises an amino acid sequence selected from the group consisting of 104HXHXDH109˜60aa˜H169˜21aa˜D191 and 103HXHXDH108˜72aa˜H180˜21aa˜D202, and to expression vectors and transformed plant and animal cells comprising the same. The proteins encoded by these nucleic acid molecules provide to a susceptible plant or animal increased resistance to a disease the virulence of which is regulated by autoinducers. Also provided are methods of increasing disease resistance in susceptible plants and animals.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: August 12, 2008
    Assignee: Institute of Molecular Agrobiology
    Inventors: Lianhui Zhang, Yihu Dong, Haibao Zhang, Jinling Xu
  • Patent number: 7407788
    Abstract: The present invention provides a novel ?-glucosidase nucleic acid sequence, designated bgl7, and the corresponding BGL7 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding BGL7, recombinant BGL7 proteins and methods for producing the same.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: August 5, 2008
    Assignee: Danisco A/S, Genencor Division
    Inventors: Nigel Dunn-Coleman, Michael Ward
  • Patent number: 7404977
    Abstract: The present invention describes an aspartic protease produced by a fungus from the class Eurotiomycetes, comprising the amino acid sequence of FDTGSSD or FDTGSSE. The present invention further provides a process for identifying new milk clotting enzymes comprising screening an amino acid sequence for the presence of FDTGSSD or FDTGSSE. The enzymes of the invention may he useful in cheese production.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: July 29, 2008
    Assignee: DSM IP Assets B.V.
    Inventor: Petrus Jacobus Theodorus Dekker
  • Patent number: 7402406
    Abstract: The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: July 22, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiko Morita, Hiroyuki Arakawa, Mayako Yamazaki, Susumu Satoh, Shintaro Nishimura, Yasuhiro Kita, Takao Yamazaki
  • Patent number: 7384772
    Abstract: The present invention relates to chitin degradative systems, in particular to systems containing enzymes that bind to and depolymerize chitin. These systems have a number of applications. The present invention also describes enzymes with at least two catalytic domains in which the domains are separated by poly-amino acid linkers.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: June 10, 2008
    Assignee: The University of Maryland
    Inventors: Michael Howard, Steven Wayne Hutcheson, Ronald M. Weiner
  • Patent number: 7348170
    Abstract: Lysyl oxidase derived from filamentous fungi and a DNA encoding thereof are provided. Lysyl oxidase including a protein described in of the following (a) or (b): (a) a protein having an amino acid sequence set forth in SEQ ID NO: 2; or (b) a protein having an amino acid sequence obtained by modifying a part of the amino acid sequence set forth in SEQ ID NO: 2, and functioning as lysyl oxidase.
    Type: Grant
    Filed: December 25, 2002
    Date of Patent: March 25, 2008
    Assignees: Amano Enzyme Inc., National Institute of Advanced Industrial Science and Technology, National Institute of Technology and Evaluation, National Research Institute of Brewing
    Inventors: Kensuke Yuuki, Atsuki Toumoto, Masayuki Machida, Keietsu Abe, Katsuya Gomi, Kiyoshi Asai, Motoaki Sano, Taishin Kin, Hideki Nagasaki, Akira Hosoyama, Osamu Akita, Naotake Ogasawara, Satoru Hisahara
  • Patent number: 7344886
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: March 18, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Patent number: 7338780
    Abstract: A method is disclosed that allows the production of peptides having three or more amino acid residues easily, inexpensively and at high yield without going through a complex synthesis method. A novel enzyme that efficiently produces a peptide from bacteria belonging to the genus Empedobacter or the genus Sphingobacterium is provided. The enzyme acts on a carboxy component and an amine component to form peptides having three or more amino acid residues by acting on a carboxy component and an amine component.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: March 4, 2008
    Assignee: Ajinomoto Co., Inc.
    Inventors: Kenzo Yokozeki, Sonoko Suzuki, Seiichi Hara, Isao Abe